Loading data
TNXPNasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 13.11 m USD | 10.09 m USD | 7.77 m USD | — | — |
| Cost of revenue | 6.64 m USD | 7.77 m USD | 4.74 m USD | — | — |
| Research and development expense | 44.49 m USD | 39.97 m USD | 86.66 m USD | 81.88 m USD | 68.84 m USD |
| Selling, general and administrative expense | 87.68 m USD | 40.1 m USD | 34.75 m USD | 30.22 m USD | — |
| Operating profit | -125.7 m USD | -136.7 m USD | -118.38 m USD | -112.09 m USD | -92.31 m USD |
| Net income (reported basis) | -124 m USD | -130 m USD | -117 m USD | -110 m USD | -92.29 m USD |
| Net income attributable to common shareholders | -124.02 m USD | -130.04 m USD | -116.66 m USD | -116.88 m USD | -92.29 m USD |
| Basic earnings per share | -14.57 USD/share | -176.6 USD/share | -14,720.25 USD/share | -20.01 USD/share | -8.1 USD/share |
| Diluted earnings per share | -14.57 USD/share | -176.6 USD/share | -14,720.25 USD/share | -20.01 USD/share | -8.1 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.